Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian In Vitro Assay Policy Update | OpenPa…
    Ask Trek AI about this page
    ModifiedPresbyterian Health PlanPolicy AHS - G2100

    In Vitro Chemoresistance and Chemosensitivity Assays

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy AHS - G2100 alerts

    Get alerted when Policy AHS - G2100 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of laboratory assays that test whether a patient's tumor cells are sensitive or resistant to chemotherapy drugs or drug combinations. Coverage depends on the member's benefit plan, and applicable government coverage policies take precedence when they conflict with this policy.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyIn Vitro Chemoresistance and Chemosensitivity Assays
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFebruary 1, 2026
    Next Review DateN/A
    Key ActionDo not request coverage for in vitro chemosensitivity or chemoresistance assays because published evidence is insufficient to confirm clinical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was reviewed and updated on September 4, 2025, including the background, guidelines and recommendations, and scientific references.

    CPT code 0285U was revised through an off-cycle coding modification effective July 1, 2025.

    CPT code 0525U was added through an off-cycle coding modification effective January 1, 2025.

    The policy was reviewed and updated on September 4, 2024, including the background, guidelines and recommendations, and scientific references.

    The policy was adopted by Presbyterian Health Plan for all lines of business on January 1, 2025.

    A New Mexico Medicaid link was added to the applicable state and federal regulations section.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Assay categories not meeting coverage criteria
    Not coveredIn vitro chemosensitivity assays
    Not coveredIn vitro chemoresistance assays
    2Off-cycle coding modifications
    4U-code laboratory procedures listed

    Coverage Criteria

    In vitro chemosensitivity and chemoresistance assays

    The following tests do not meet coverage criteria due to a lack of available published scientific literature confirming that the tests are required and beneficial for diagnosing or treating an individual's illness.

    In vitro chemosensitivity assays, including histoculture drug response assays and fluorescent cytoprint assays, do not meet coverage criteria.

    Not covered.

    In vitro chemoresistance assays, including extreme drug resistance (EDR) assays, do not meet coverage criteria.

    Not covered.

    In vitro chemosensitivity assays, including histoculture drug response assays and fluorescent cytoprint assays, do not meet coverage criteria and are excluded from coverage.

    In vitro chemoresistance assays, including extreme drug resistance (EDR) assays, do not meet coverage criteria and are excluded from coverage.

    These assays do not meet coverage criteria because published scientific literature does not confirm that they are required and beneficial for the diagnosis and treatment of an individual's illness.

    Applicable Procedure Codes and Assay Panels

    Applicable CPT/HCPCS Procedure CodesCPT
    81536Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure). Proprietary test: ChemoFX®; Lab/manufacturer: Helomics, Corp.
    86849Unlisted immunology procedure.
    88104Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation.
    88199Unlisted cytopathology procedure.
    88305Level IV - Surgical pathology, gross and microscopic examination.
    88313Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or ...
    88358Morphometric analysis; tumor (eg, DNA ploidy).
    89050Cell count, miscellaneous body fluids (eg, cerebrospinal fluid, joint fluid), except ...
    Applicable CPT/HCPCS Procedure CodesCPT
    81535Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination. Proprietary test: ChemoFX®; lab/manufacturer: Helomics, Corp.
    81536Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination. Proprietary test: ChemoFX®; lab/manufacturer: Helomics, Corp.
    86849Unlisted immunology procedure.
    88104Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation.
    88199Unlisted cytopathology procedure.
    88305Level IV - Surgical pathology, gross and microscopic examination.
    88313Special stain including interpretation and report; Group II, all other, such as iron and trichrome, except stains for microorganisms and stains for enzyme constituents.
    88358Immunocytochemistry and immunohistochemistry.
    89050Cell count, miscellaneous body fluids, such as cerebrospinal fluid and joint fluid, except blood.
    89398Unlisted miscellaneous pathology test.
    1–10 of 16
    1/2
    ChemoID chemotherapeutic drug panel
    Minimum panel sizeMinimum of 14 drugs or drug combinations
    3D Predict Ovarian drug panel
    Panel composition11-drug panel: carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, and veliparib
    Theralink RPPA analyte panel
    Analyte panel32 phosphoproteins and protein analytes

    Provider and Coverage Guidance

    Denial Risk

    Insufficient Evidence of Clinical Benefit

    Requests for in vitro chemosensitivity assays do not meet coverage criteria because published scientific literature is insufficient to confirm that these tests are required and beneficial for diagnosing or treating an individual's illness.

    Denial Risk

    Specified Assays Are Not Covered

    Requests for in vitro chemoresistance assays do not meet coverage criteria. This includes the specified assay types below and other comparable in vitro chemosensitivity or chemoresistance assays lacking sufficient evidence of clinical benefit.

    • Histoculture drug response assay
    • Fluorescent cytoprint assay
    • Extreme drug resistance (EDR) assay

    Clinical and Laboratory Background

    In vitro chemotherapy sensitivity and resistance assays expose tumor cells obtained from a patient to one or more chemotherapy agents or drug combinations outside the body. The assays then assess measures such as cell survival, treatment response, or drug-induced apoptosis to characterize the tumor as responsive, non-responsive, sensitive, or resistant.

    Definitions and Abbreviations

    Definition
    ATP-CRAAdenosine triphosphate-based chemotherapy response assay.
    Definition
    ATP-TCAAdenosine triphosphate-tumor chemosensitivity.
    Definition
    CLIA '88Clinical Laboratory Improvement Amendments of 1988.
    Definition
    EDR

    Non-Covered Services

    The following assay categories are not covered: in vitro chemosensitivity assays, including histoculture drug response assays and fluorescent cytoprint assays; and in vitro chemoresistance assays, including extreme drug resistance (EDR) assays.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyIn Vitro Chemoresistance and Chemosensitivity Assays
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateFebruary 1, 2026
    Next Review DateN/A
    Key ActionDo not request coverage for in vitro chemosensitivity or chemoresistance assays because published evidence is insufficient to confirm clinical benefit.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Procedure Codes and Assay PanelsProvider and Coverage GuidanceClinical and Laboratory BackgroundDefinitions and AbbreviationsNon-Covered Services
    Billing Rule

    Government Policy Supersedes When Applicable

    When a relevant government policy conflicts with this policy for a particular member, the government policy controls the coverage determination. Apply the most current applicable Medicare, Medicaid, LCD, NCD, or state coverage policy.

    • For Medicare, review applicable Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs).
    • For Medicaid, apply the applicable state coverage policy and requirements.
    • Coverage criteria remain dependent on the individual's benefit coverage at the time of the request.
    Extreme drug resistance.
    Definition
    HDRAHistoculture drug response assay.
    Definition
    LDTLaboratory-developed test.
    Definition
    MiCKMicroculture-kinetic.
    Definition
    DISCDifferential staining cytotoxicity.
    Definition
    NCCNNational Comprehensive Cancer Network.
    Laboratory-developed test (LDT)
    Laboratory-developed test (LDT)A test developed by a laboratory that is validated and performed in-house.
    CLIA high-complexity test
    CLIA high-complexity testLaboratory-developed tests are regulated by the Centers for Medicare and Medicaid Services as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).